Newsfeeds - Spark Newswire

5 minute read

Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More

By Lara Goldstein

Today, 1:57 PM

Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial

ATAI

6 minute read

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More

By Lara Goldstein

Today, 1:57 PM

Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and added to the list of measures calling for some sort of psychedelics legalization, while some of the already filed ones continue progressing and others get a thumbs down.

AGNPF

2 minute read

Short-Acting Psychedelics: DMT-Based Drug Therapy Gets Tested In New Clinical Trial

By Lara Goldstein

Today, 1:57 PM

Psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) has dosed the first subject in its first-in-human clinical trial assessing proprietary DMT drug SPL028 paired with supportive therapy.

DMTTF

2 minute read

Race Is On For Psychedelic DMT-Related Compounds, Small Pharma, Inc To Issue Two New Patents

By Lara Goldstein

Today, 1:57 PM

After the positive results provided by its clinical trial assessing novel DMT’s effects on patients with Major Depressive Disorder (MDD), psychedelics biotech Small Pharma Inc.

DMTTF

3 minute read

Small Pharma, Inc’s Psychedelics For Major Depression Trial Results And Q1 Earnings

By Lara Goldstein

Today, 1:57 PM

Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF)’s proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase 2a trial for the treatment of Major Depressive Disorder (MDD).

DMTTF

2 minute read

This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage

By Lara Goldstein

Today, 1:57 PM

Short-acting psychedelics biotech company Small Pharma Inc.

DMTTF

2 minute read

Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing

By Lara Goldstein

Today, 1:57 PM

Psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) confirmed that the first patient has been dosed in its Phase 1b study assessing the interaction between selective serotonin reuptake inhibitors (SSRIs) and proprietary lead DMT candidate SPL026 in patients with Major Depressive Disorder (MDD).

DMTTF